Our data showed that higher ARPC5 expression was associated with higher TMB and lower immune response score in glioma, which meant that means that targeted inhibition of ARPC5 may become an attractive immunotherapy strategy in the treatment of glioma. The gene discussed is ARPC5; the disease is central nervous system cancer.